{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:19:14Z","timestamp":1783059554044,"version":"3.54.6"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The effect of pegylated interferon \u03b1-2b (Peg-IFNalpha-2b) on lipid metabolism in chronic hepatitis B (CHB) patients remains controversial. This study aimed to investigate the dynamic changes of low-density lipoprotein (LDL) levels during different antiviral regimens and explore their potential clinical significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 585 CHB patients were enrolled in this real-world cohort study and divided into three groups: nucleos(t)ide analogs (NAs) monotherapy group (\n                      <jats:italic>n<\/jats:italic>\n                      = 96), NAs + Peg-IFNalpha-2b combination group (\n                      <jats:italic>n<\/jats:italic>\n                      = 396), and Peg-IFNalpha-2b monotherapy group (\n                      <jats:italic>n<\/jats:italic>\n                      = 93). Serum lipid levels were monitored at baseline and weeks 12, 24, 36, and 48. Generalized additive mixed models were used to adjust for key confounders including sex, age, body mass index (BMI), fatty liver status, cirrhosis, HBV DNA, HBsAg, HBeAg and so on.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After 48 weeks of treatment, LDL levels decreased by 0.3\u20130.4 mmol\/L in the Peg-IFNalpha-2b monotherapy group compared with baseline, with an intermediate reduction in the combination group and no significant change in the NAs monotherapy group. The association remained significant after adjusting for key confounders (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05), with consistent results across subgroups such as age, gender and fatty liver status.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Peg-IFNalpha-2b treatment significantly reduces LDL levels in CHB patients. This mild but consistent LDL reduction may bring potential long-term cardiovascular and hepatic benefits, especially for patients with comorbid metabolic disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1787001","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:38:32Z","timestamp":1783057112000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of pegylated interferon \u03b1-2b on low-density lipoprotein in patients with chronic hepatitis B"],"prefix":"10.3389","volume":"13","author":[{"given":"Baiguo","family":"Xu","sequence":"first","affiliation":[{"name":"Tianjin Third Central Hospital","place":["Tianjin, China"]},{"name":"Central Hospital, Tianjin University","place":["Tianjin, China"]},{"name":"Tianjin Institute of Hepatobiliary Disease","place":["Tianjin, China"]},{"name":"Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases","place":["Tianjin, China"]},{"name":"Artificial Cell Engineering Technology Research Center","place":["Tianjin, China"]},{"name":"The Third Central Clinical College of NanKai University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aili","family":"Fan","sequence":"additional","affiliation":[{"name":"Tianjin Third Central Hospital","place":["Tianjin, China"]},{"name":"Central Hospital, Tianjin University","place":["Tianjin, China"]},{"name":"The Third Central Clinical College of NanKai University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoxin","family":"Qian","sequence":"additional","affiliation":[{"name":"Central Hospital, Tianjin University","place":["Tianjin, China"]},{"name":"Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases","place":["Tianjin, China"]},{"name":"Artificial Cell Engineering Technology Research Center","place":["Tianjin, China"]},{"name":"The Third Central Clinical College of NanKai University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liang","sequence":"additional","affiliation":[{"name":"Central Hospital, Tianjin University","place":["Tianjin, China"]},{"name":"Tianjin Institute of Hepatobiliary Disease","place":["Tianjin, China"]},{"name":"Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases","place":["Tianjin, China"]},{"name":"The Third Central Clinical College of NanKai University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinghong","family":"Li","sequence":"additional","affiliation":[{"name":"Central Hospital, Tianjin University","place":["Tianjin, China"]},{"name":"Tianjin Institute of Hepatobiliary Disease","place":["Tianjin, China"]},{"name":"Artificial Cell Engineering Technology Research Center","place":["Tianjin, China"]},{"name":"The Third Central Clinical College of NanKai University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Yin","sequence":"additional","affiliation":[{"name":"Tianjin Third Central Hospital","place":["Tianjin, China"]},{"name":"Central Hospital, Tianjin University","place":["Tianjin, China"]},{"name":"Tianjin Institute of Hepatobiliary Disease","place":["Tianjin, China"]},{"name":"Artificial Cell Engineering Technology Research Center","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Xiang","sequence":"additional","affiliation":[{"name":"Tianjin Third Central Hospital","place":["Tianjin, China"]},{"name":"Central Hospital, Tianjin University","place":["Tianjin, China"]},{"name":"Tianjin Institute of Hepatobiliary Disease","place":["Tianjin, China"]},{"name":"Artificial Cell Engineering Technology Research Center","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Ye","sequence":"additional","affiliation":[{"name":"Central Hospital, Tianjin University","place":["Tianjin, China"]},{"name":"Tianjin Institute of Hepatobiliary Disease","place":["Tianjin, China"]},{"name":"Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases","place":["Tianjin, China"]},{"name":"Artificial Cell Engineering Technology Research Center","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.hco.0000200416.65370.a0","article-title":"Diagnosis and management of the metabolic syndrome: an American heart association\/national heart, lung, and blood institute scientific statement","volume":"21","author":"Grundy","year":"2006","journal-title":"Curr Opin Cardiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e32730","DOI":"10.1016\/j.heliyon.2024.e32730","article-title":"Interferon-\u03b1 could induce liver steatosis to promote HBsAg loss by increasing triglyceride level","volume":"10","author":"Wu","year":"2024","journal-title":"Heliyon"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1186\/s12879-024-10093-w","article-title":"Effect of dyslipidemia on HBsAg clearance in nucleos(t)ide analogues-experienced chronic hepatitis B patients treated with peginterferon alfa","volume":"24","author":"Song","year":"2024","journal-title":"BMC Infect Dis."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1001-5256.2019.12.007","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)","year":"2019","journal-title":"J Clin Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of chronic hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3760\/cma.j.cn501113-20240327-00163","article-title":"Metabolic associated (non-alcoholic) fatty liver disease prevention and treatment guidelines (2024 edition)","volume":"32","year":"2024","journal-title":"Chin J Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL clinical practice guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","journal-title":"J Hepatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1499-3872(16)60132-7","article-title":"The association of non-alcoholic fatty liver disease and metabolic syndrome in a Chinese population","volume":"16","author":"Lee","year":"2017","journal-title":"Hepatobiliary Pancreat Dis Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4103\/aam.aam_35_21","article-title":"The evaluation of serum lipid profile in chronic Hepatitis B patients at a tertiary care centre in Western India: a cross-sectional study","volume":"21","author":"Meena","year":"2022","journal-title":"Ann Afr Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00508-019-01544-5","article-title":"Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease","volume":"131","author":"Unger","year":"2019","journal-title":"Wien Klin Wochenschr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12944-019-1084-6","article-title":"Serum apolipoprotein C3 levels are negatively associated with hepatitis B virus DNA in HBeAg-negative chronic hepatitis B patients","volume":"18","author":"Cui","year":"2019","journal-title":"Lipids Health Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.23736\/S2724-5985.26.03992-6","article-title":"Investigation of the effects of antivirals used in hepatitis B treatment on blood lipid profile: a retrospective real-life data analysis","volume":"72","author":"Karabay","year":"2026","journal-title":"Minerva Gastroenterol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s12072-023-10528-7","article-title":"Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis","volume":"17","author":"Hwang","year":"2023","journal-title":"Hepatol Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3350\/cmh.2021.0314","article-title":"Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: a propensity score-matched analysis","volume":"28","author":"Jeong","year":"2022","journal-title":"Clin Mol Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/apt.17765","article-title":"Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B","volume":"59","author":"Cheng","year":"2024","journal-title":"Aliment Pharmacol Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.cld.2021.06.004","article-title":"Controversies in treating chronic HBV: the role of PEG-interferon-alfa","volume":"25","author":"Charatcharoenwitthaya","year":"2021","journal-title":"Clin Liver Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"20059","DOI":"10.1074\/jbc.R700016200","article-title":"JAK-STAT signaling: from interferons to cytokines","volume":"282","author":"Schindler","year":"2007","journal-title":"J Biol Chem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"908","DOI":"10.5604\/01.3001.0012.7191","article-title":"Immunometabolic effect of cholesterol in hepatitis C infection: implications in clinical management and antiviral therapy","volume":"17","author":"Gonz\u00e1lez-Aldaco","year":"2018","journal-title":"Ann Hepatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3389\/fimmu.2016.00634","article-title":"Interferon control of the sterol metabolic network: bidirectional molecular circuitry-mediating host protection","volume":"7","author":"Robertson","year":"2016","journal-title":"Front Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1016\/j.cgh.2021.04.031","article-title":"Switching to or add-on peginterferon in patients on nucleos(t)ide analogues for chronic hepatitis B: the SWAP RCT","volume":"20","author":"Lim","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(95)80012-H","article-title":"Dense low density lipoproteins and coronary artery disease","author":"Krauss","year":"1995","journal-title":"Am J Cardiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa010492","article-title":"Diet, lifestyle, and the risk of type 2 diabetes mellitus in women","volume":"345","author":"Hu","year":"2001","journal-title":"N Engl J Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.hbpd.2025.04.007","article-title":"The outcomes and mechanisms of chronic hepatitis B complicated by metabolic dysfunction-associated steatotic liver disease","volume":"24","author":"Li","year":"2025","journal-title":"Hepatobiliary Pancreat Dis Int."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e70042","DOI":"10.1111\/liv.70042","article-title":"The association between metabolic dysfunction-associated steatotic liver disease and change in liver stiffness in patients with chronic hepatitis B","volume":"45","author":"Patmore","year":"2025","journal-title":"Liver Int."},{"key":"B31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.23736\/S2724-5985.25.03862-8","article-title":"Pathogenesis, diagnosis and management of chronic hepatitis B related liver fibrosis","volume":"71","author":"Kosekli","year":"2025","journal-title":"Minerva Gastroenterol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7754\/Clin.Lab.2019.190525","article-title":"Serum lipid metabolic derangement is associated with disease progression during chronic HBV infection","author":"Cao","year":"2019","journal-title":"Clin Lab."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists' (CTT) Collaboration","year":"2010","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.cmet.2025.01.020","article-title":"EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis","volume":"37","author":"Ma","year":"2025","journal-title":"Cell Metab"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1787001\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:38:34Z","timestamp":1783057114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1787001\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":34,"alternative-id":["10.3389\/fmed.2026.1787001"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1787001","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"article-number":"1787001"}}